Insilico Medicine to Present AI-Designed Cancer Drug Data at ESMO 2026

The study, which evaluates the safety and preliminary efficacy of ISM6331, focuses on the Hippo signaling pathway—a biological mechanism frequently implicated in therapeutic resistance. Small-molecule inhibition of this pathway has historically proven difficult, but Insilico’s platform, Chemistry42, was used to design the inhibitor specifically to address these medicinal chemistry hurdles.

Feng Ren, Co-CEO and Chief Scientific Officer, noted that the Rapid Oral presentation selection underscores the potential of generative AI to tackle complex oncogenic drivers. The clinical data, categorized under abstract #997, is scheduled for discussion on October 25, 2026, in the Cordoba Auditorium. Halle Zhang, Vice President of Clinical Development, emphasized that the trial aims to provide new options for patients who currently face limited alternatives for Hippo-driven malignancies. The ongoing global study continues to assess pharmacokinetics and antitumor activity to guide future development phases.